<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00412022</url>
  </required_header>
  <id_info>
    <org_study_id>HOBOE</org_study_id>
    <nct_id>NCT00412022</nct_id>
  </id_info>
  <brief_title>HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer.</brief_title>
  <acronym>HOBOE</acronym>
  <official_title>Phase III Randomized Study of the Effects on Bone Mineral Density of Tamoxifen, Letrozole, and Letrozole + Zoledronic Acid as Adjuvant Treatment of Patients With Early Breast Cancer; VERSION 2 AMENDED Phase 3 Study of Triptorelin and Tamoxifen, Letrozole, or Letrozole + Zoledronic Acid in Adjuvant Treatment of Premenopausal Endocrine Responsive Breast Cancer Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Naples</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Campania &quot;Luigi Vanvitelli&quot;</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute, Naples</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The HOBOE study was amended in November 2009, and, after reaching enrollment of the first 500
      patients, the study began recruiting premenopausal patients only. The primary objective of
      the extended study is to compare disease free survival in premenopausal patients with early
      breast cancer. Patients receive triptorelin and are randomized in a 1:1:1 fashion to receive
      tamoxifen or letrozole, or letrozole + zoledronic acid.

      The purpose of the HOBOE study, Version 1, was to compare the adjuvant hormonal therapy
      treatments of Tamoxifen, Letrozole and Letrozole + Zoledronate for their effects on bone loss
      in breast cancer patients. Postmenopausal and premenopausal patients were eligible, the
      latter also receiving monthly triptorelin. Upon reaching the enrollment of the first 500
      patients in March 2010, the study began recruiting premenopausal patients only.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease free survival in premenopausal patients</measure>
    <time_frame>observation period is 10 years from initiation of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>bone mineral density</measure>
    <time_frame>12 months from initiation of therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone mineral density measured</measure>
    <time_frame>yearly after first year of therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease free survival in postmenopausal patients</measure>
    <time_frame>observation period is 10 years from initiation of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>observation period is 10 years from initiation of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicity of letrozole + triptorelin and letrozole + zoledronic acid + triptorelin in premenopausal patients</measure>
    <time_frame>monthly</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1294</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Triptorelin 3.75 mg IM every 4 weeks and Tamoxifen 20 mg daily, for 5 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Triptorelin 3.75 mg IM every 4 weeks and Letrozole 2.5 mg daily, for 5 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Triptorelin 3.75 mg IM every 4 weeks and Letrozole 2.5 mg daily for 5 years + zoledronic acid 4 mg every 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamoxifen</intervention_name>
    <description>20 mg daily for 5 years</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triptorelin</intervention_name>
    <description>Premenopausal patients will receive triptorelin 3.75 mg IM at the beginning of therapy and every 4 weeks for 5 years or up to age 55</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>letrozole</intervention_name>
    <description>2.5 mg daily for 5 years</description>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zoledronic acid</intervention_name>
    <description>4 mg every 6 months</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological diagnosis of breast cancer

          -  Surgical resection of breast cancer (breast conserving surgery or mastectomy)

          -  No evidence of disease

          -  Indication for adjuvant hormonal therapy (ER and/or PgR positive with IHC exam in at
             least 1% of primary tumor cells, according to St. Gallen criteria)

          -  Patient age at least 18 years

          -  Written informed consent . Premenopausal status defined as LMP within 12 months of
             randomization (FSH, LH will not be considered as determinants of menopausal status due
             the chemotherapy induced reversible ovarian suppression)

        Please note that patients who have received neoadjuvant or adjuvant chemotherapy and/or
        locoregional radiation therapy may be included in the study

        Exclusion Criteria:

          -  Performance status (ECOG)&gt;2.

          -  Previous or concomitant malignancy (with the exception of adequately treated
             nonmalignant skin cancer and carcinoma in situ of the uterine cervix

          -  Metastatic breast cancer

          -  Creatinine &gt; 1.25 times the value of upper normal limit

          -  Pregnant or lactating females

          -  Clinical or radiologic evidence of bone fractures

          -  Treatment with systemic cortisone therapy within 12 months prior to randomization

          -  Treatment with drugs that could alter bone metabolism (calcitonin, mithramycin,
             gallium nitrate) within 2 weeks prior to randomization

          -  Previous treatment with tamoxifen or aromatase inhibitors

          -  AST and/or ALT &gt; 3 times the value of upper normal limit with clinical and laboratory
             findings that indicate a grade of hepatic insufficiency that could potentially
             increase the risk of assuming letrozole

          -  Any concomitant conditions that would, in the Investigator's opinion, contraindicate
             the use of any of the drugs used in this study

          -  Inability to provide informed consent

          -  Inability to comply with followup

          -  Patient undergoing invasive dental work at time of baseline evaluation or foreseen
             during the course of adjuvant therapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea De Matteis, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI Naples, Division of Medical Oncology C</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ciro Gallo, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Campania &quot;Luigi Vanvitelli&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Perrone, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI Naples, Clinical Trials Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>S. Giuseppe Moscati</name>
      <address>
        <city>Avellino</city>
        <state>AV</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Treviglio - Caravaggio</name>
      <address>
        <city>Treviglio</city>
        <state>BG</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera G. Rummo</name>
      <address>
        <city>Benevento</city>
        <state>BN</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Senatore Antonio Perrino</name>
      <address>
        <city>Brindisi</city>
        <state>BR</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Romagnolo per lo Studio e la Cura dei Tumori</name>
      <address>
        <city>Meldola</city>
        <state>FC</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero Di Saronno Aziendo Ospedaliera di Busto Arsizio</name>
      <address>
        <city>Saronno</city>
        <state>VA</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Maria Annunziata</name>
      <address>
        <city>Bagno a Ripoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale per la ricerca Sul Cancro</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Riuniti</name>
      <address>
        <city>Livorno</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Unico della Versilia</name>
      <address>
        <city>Lucca</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori,</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Cardarelli</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seconda Università di Napoli</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università Federico II, Cattedra di Oncologia Medica</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Casa di Cura La Maddalena</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Silvestrini</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Chiara</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università di Sassari</name>
      <address>
        <city>Sassari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Chiara</name>
      <address>
        <city>Trento</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASL Viterbo Ospedale Belcolle</name>
      <address>
        <city>Viterbo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Rossi E, Morabito A, Di Rella F, Esposito G, Gravina A, Labonia V, Landi G, Nuzzo F, Pacilio C, De Maio E, Di Maio M, Piccirillo MC, De Feo G, D'Aiuto G, Botti G, Chiodini P, Gallo C, Perrone F, de Matteis A. Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial. J Clin Oncol. 2009 Jul 1;27(19):3192-7. doi: 10.1200/JCO.2008.18.6213. Epub 2009 Apr 20.</citation>
    <PMID>19380451</PMID>
  </results_reference>
  <results_reference>
    <citation>Rossi E, Morabito A, De Maio E, Di Rella F, Esposito G, Gravina A, Labonia V, Landi G, Nuzzo F, Pacilio C, Piccirillo MC, D'Aiuto G, D'Aiuto M, Rinaldo M, Botti G, Gallo C, Perrone F, de Matteis A. Endocrine effects of adjuvant letrozole + triptorelin compared with tamoxifen + triptorelin in premenopausal patients with early breast cancer. J Clin Oncol. 2008 Jan 10;26(2):264-70. Epub 2007 Dec 17.</citation>
    <PMID>18086795</PMID>
  </results_reference>
  <results_reference>
    <citation>Nuzzo F, Gallo C, Lastoria S, Di Maio M, Piccirillo MC, Gravina A, Landi G, Rossi E, Pacilio C, Labonia V, Di Rella F, Bartiromo A, Buonfanti G, De Feo G, Esposito G, D'Aniello R, Maiolino P, Signoriello S, De Maio E, Tinessa V, Colantuoni G, De Laurentiis M, D'Aiuto M, Di Bonito M, Botti G, Giordano P, Daniele G, Morabito A, Normanno N, de Matteis A, Perrone F. Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study. Ann Oncol. 2012 Aug;23(8):2027-33. doi: 10.1093/annonc/mdr600. Epub 2012 Mar 12.</citation>
    <PMID>22412041</PMID>
  </results_reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2006</study_first_submitted>
  <study_first_submitted_qc>December 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2006</study_first_posted>
  <last_update_submitted>July 14, 2017</last_update_submitted>
  <last_update_submitted_qc>July 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>early breast cancer</keyword>
  <keyword>adjuvant therapy</keyword>
  <keyword>premenopause</keyword>
  <keyword>premenopausal</keyword>
  <keyword>menopausal status</keyword>
  <keyword>postmenopause</keyword>
  <keyword>bone mineral density</keyword>
  <keyword>hormone sensitive</keyword>
  <keyword>aromatase inhibitors</keyword>
  <keyword>letrozole</keyword>
  <keyword>disease-free survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Triptorelin Pamoate</mesh_term>
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

